AG˹ٷ

STOCK TITAN

[8-K] Oscar Health, Inc. Reports Material Event

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
8-K
Rhea-AI Filing Summary

Oscar Health, Inc. (OSCR) filed a Form 8-K on 22 Jul 2025 to notify investors that it has issued a press release containing preliminary second-quarter 2025 results and a revised full-year 2025 outlook. The press release is furnished as Exhibit 99.1 and, per the filing, is not deemed “filed� under Exchange Act Section 18. No quantitative metrics, guidance figures, or additional material events are included in the body of the 8-K. Other than furnishing the exhibit, the company reported no changes to previously disclosed risk factors, transactions, or governance matters.

Oscar Health, Inc. (OSCR) ha presentato un Modulo 8-K il 22 luglio 2025 per informare gli investitori di aver pubblicato un comunicato stampa contenente i risultati preliminari del secondo trimestre 2025 e una previsione rivista per l'intero anno 2025. Il comunicato stampa è allegato come Exhibit 99.1 e, secondo quanto riportato, non è considerato "depositato" ai sensi della Sezione 18 del Exchange Act. Nel corpo del 8-K non sono inclusi dati quantitativi, indicazioni di guidance o eventi materiali aggiuntivi. A parte l'allegato, la società non ha segnalato modifiche ai fattori di rischio, alle operazioni o alle questioni di governance precedentemente comunicate.

Oscar Health, Inc. (OSCR) presentó un Formulario 8-K el 22 de julio de 2025 para notificar a los inversores que ha emitido un comunicado de prensa con los resultados preliminares del segundo trimestre de 2025 y una perspectiva revisada para todo el año 2025. El comunicado se adjunta como Exhibit 99.1 y, según el documento, no se considera "presentado" bajo la Sección 18 del Exchange Act. No se incluyen métricas cuantitativas, cifras de orientación ni eventos materiales adicionales en el cuerpo del 8-K. Aparte de proporcionar el anexo, la empresa no informó cambios en los factores de riesgo, transacciones o asuntos de gobernanza previamente divulgados.

Oscar Health, Inc. (OSCR)� 2025� 7� 22� Form 8-K� 제출하여 투자자들에게 2025� 2분기 잠정 실적2025� 전체 연도 수정 전망� 담은 보도자료� 발표했음� 알렸습니�. 보도자료� Exhibit 99.1� 제공되었으며, 제출서류� 따르� Exchange Act 섹션 18� 따른 "제출�" 것으� 간주되지 않습니다. 8-K 본문에는 정량� 지�, 가이던� 수치 또는 추가 중요� 이벤트가 포함되어 있지 않습니다. 첨부 자료 제공 외에� 회사가 이전� 공개� 위험 요소, 거래 또는 거버넌스 사항� 대� 변� 사항� 보고하지 않았습니�.

Oscar Health, Inc. (OSCR) a déposé un formulaire 8-K le 22 juillet 2025 pour informer les investisseurs qu’elle a publié un communiqué de presse contenant les résultats préliminaires du deuxième trimestre 2025 ainsi qu’une prévision révisée pour l’ensemble de l’année 2025. Le communiqué est fourni en tant qu’Exhibit 99.1 et, selon le dépôt, n’est pas considéré comme « déposé » au sens de la Section 18 du Exchange Act. Le corps du 8-K ne contient aucune donnée quantitative, chiffre d’orientation ou événement matériel supplémentaire. Hormis la fourniture de cette pièce jointe, la société n’a signalé aucun changement concernant les facteurs de risque, transactions ou questions de gouvernance déjà divulgués.

Oscar Health, Inc. (OSCR) reichte am 22. Juli 2025 ein Formular 8-K ein, um Investoren darüber zu informieren, dass eine Pressemitteilung mit vorläufigen Ergebnissen für das zweite Quartal 2025 und einem überarbeiteten Ausblick für das Gesamtjahr 2025 veröffentlicht wurde. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird gemäß Einreichung nicht als "eingereicht" im Sinne von Abschnitt 18 des Exchange Act angesehen. Im 8-K selbst sind keine quantitativen Kennzahlen, Prognosewerte oder zusätzlichen wesentlichen Ereignisse enthalten. Abgesehen von der Bereitstellung des Anhangs meldete das Unternehmen keine Änderungen an zuvor offengelegten Risikofaktoren, Transaktionen oder Governance-Themen.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: 8-K signals forthcoming numbers and guidance shift, but provides no figures—impact indeterminate until exhibit is reviewed.

The filing merely alerts investors to a separate press release with preliminary Q2-25 results and updated FY-25 outlook. Because the numerical details are in Exhibit 99.1 (not supplied here) and are furnished rather than filed, there is minimal immediate regulatory consequence. Market impact hinges on the actual figures and direction of the outlook change; without that data, the disclosure is neutral. Investors should examine the exhibit promptly to gauge revenue trends, MLR performance and profitability trajectory.

Oscar Health, Inc. (OSCR) ha presentato un Modulo 8-K il 22 luglio 2025 per informare gli investitori di aver pubblicato un comunicato stampa contenente i risultati preliminari del secondo trimestre 2025 e una previsione rivista per l'intero anno 2025. Il comunicato stampa è allegato come Exhibit 99.1 e, secondo quanto riportato, non è considerato "depositato" ai sensi della Sezione 18 del Exchange Act. Nel corpo del 8-K non sono inclusi dati quantitativi, indicazioni di guidance o eventi materiali aggiuntivi. A parte l'allegato, la società non ha segnalato modifiche ai fattori di rischio, alle operazioni o alle questioni di governance precedentemente comunicate.

Oscar Health, Inc. (OSCR) presentó un Formulario 8-K el 22 de julio de 2025 para notificar a los inversores que ha emitido un comunicado de prensa con los resultados preliminares del segundo trimestre de 2025 y una perspectiva revisada para todo el año 2025. El comunicado se adjunta como Exhibit 99.1 y, según el documento, no se considera "presentado" bajo la Sección 18 del Exchange Act. No se incluyen métricas cuantitativas, cifras de orientación ni eventos materiales adicionales en el cuerpo del 8-K. Aparte de proporcionar el anexo, la empresa no informó cambios en los factores de riesgo, transacciones o asuntos de gobernanza previamente divulgados.

Oscar Health, Inc. (OSCR)� 2025� 7� 22� Form 8-K� 제출하여 투자자들에게 2025� 2분기 잠정 실적2025� 전체 연도 수정 전망� 담은 보도자료� 발표했음� 알렸습니�. 보도자료� Exhibit 99.1� 제공되었으며, 제출서류� 따르� Exchange Act 섹션 18� 따른 "제출�" 것으� 간주되지 않습니다. 8-K 본문에는 정량� 지�, 가이던� 수치 또는 추가 중요� 이벤트가 포함되어 있지 않습니다. 첨부 자료 제공 외에� 회사가 이전� 공개� 위험 요소, 거래 또는 거버넌스 사항� 대� 변� 사항� 보고하지 않았습니�.

Oscar Health, Inc. (OSCR) a déposé un formulaire 8-K le 22 juillet 2025 pour informer les investisseurs qu’elle a publié un communiqué de presse contenant les résultats préliminaires du deuxième trimestre 2025 ainsi qu’une prévision révisée pour l’ensemble de l’année 2025. Le communiqué est fourni en tant qu’Exhibit 99.1 et, selon le dépôt, n’est pas considéré comme « déposé » au sens de la Section 18 du Exchange Act. Le corps du 8-K ne contient aucune donnée quantitative, chiffre d’orientation ou événement matériel supplémentaire. Hormis la fourniture de cette pièce jointe, la société n’a signalé aucun changement concernant les facteurs de risque, transactions ou questions de gouvernance déjà divulgués.

Oscar Health, Inc. (OSCR) reichte am 22. Juli 2025 ein Formular 8-K ein, um Investoren darüber zu informieren, dass eine Pressemitteilung mit vorläufigen Ergebnissen für das zweite Quartal 2025 und einem überarbeiteten Ausblick für das Gesamtjahr 2025 veröffentlicht wurde. Die Pressemitteilung ist als Exhibit 99.1 beigefügt und wird gemäß Einreichung nicht als "eingereicht" im Sinne von Abschnitt 18 des Exchange Act angesehen. Im 8-K selbst sind keine quantitativen Kennzahlen, Prognosewerte oder zusätzlichen wesentlichen Ereignisse enthalten. Abgesehen von der Bereitstellung des Anhangs meldete das Unternehmen keine Änderungen an zuvor offengelegten Risikofaktoren, Transaktionen oder Governance-Themen.

0001568651FALSE00015686512025-07-222025-07-22

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): July 22, 2025
Oscar Health, Inc.
(Exact Name of Registrant as Specified in its Charter)
Delaware001-4015446-1315570
(State or Other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)

75 Varick Street, 5th Floor
New York, New York 10013
(Address of Principal Executive Offices) (Zip Code)
(646) 403-3677
(Registrant’s telephone number, including area code)
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbols
Name of each exchange
on which registered
Class A Common Stock, $0.00001 par value per shareOSCRNew York Stock Exchange
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 2.02. Results of Operations and Financial Condition.
On July 22, 2025, Oscar Health, Inc. (the “Company”) issued a press release announcing certain preliminary financial results for the second quarter of 2025 and revising its full year 2025 outlook. A copy of the press release issued in connection with the announcement is attached and furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in Item 2.02 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information and exhibits be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.Description
99.1
Press Release, dated July 22, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document).



SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Oscar Health, Inc.
By:/s/ R. Scott Blackley
Name:R. Scott Blackley
Title:Chief Financial Officer
Date: July 22, 2025

Oscar Health Inc

NYSE:OSCR

OSCR Rankings

OSCR Latest News

OSCR Latest SEC Filings

OSCR Stock Data

3.84B
203.16M
3.32%
92.14%
8.9%
Healthcare Plans
Hospital & Medical Service Plans
United States
NEW YORK